Envestnet Asset Management
CPRX

Envestnet Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Envestnet Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
33,093
-85,507
-72% -$2.52M ﹤0.01% 3608
2026
Q1 		$2.94M Buy
118,600
+55,887
+89% +$1.33M ﹤0.01% 2720
2025
Q4 		$1.46M Sell
62,713
-36,657
-37% -$817K ﹤0.01% 3052
2025
Q3 		$1.96M Sell
99,370
-2,237
-2% -$46K ﹤0.01% 2892
2025
Q2 		$2.2M Buy
101,607
+23,412
+30% +$553K ﹤0.01% 2759
2025
Q1 		$1.9M Buy
78,195
+13,800
+21% +$311K ﹤0.01% 2772
2024
Q4 		$1.34M Buy
64,395
+39,836
+162% +$856K ﹤0.01% 2958
2024
Q3 		$488K Sell
24,559
-6,919
-22% -$128K ﹤0.01% 3548
2024
Q2 		$488K Buy
31,478
+1,366
+5% +$21.3K ﹤0.01% 3472
2024
Q1 		$480K Sell
30,112
-6,603
-18% -$99.5K ﹤0.01% 3456
2023
Q4 		$617K Buy
36,715
+13,706
+60% +$187K ﹤0.01% 3210
2023
Q3 		$269K Buy
23,009
+1,120
+5% +$15K ﹤0.01% 3583
2023
Q2 		$294K Buy
21,889
+3,153
+17% +$45.4K ﹤0.01% 3499
2023
Q1 		$311K Buy
+18,736
New +$309K ﹤0.01% 3425

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management's CPRX Position: Q2 2026 in Review

Envestnet Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 72% in Q2 2026, selling an estimated $2.52M and leaving 33,093 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3608.

Envestnet Asset Management first reported a position in CPRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.94M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Envestnet Asset Management held 33,093 shares of Catalyst Pharmaceutical worth $1.04M as of Q2 2026.
  • Envestnet Asset Management sold 85,507 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.52M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3608 holding.
  • Envestnet Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
  • Envestnet Asset Management's Catalyst Pharmaceutical position peaked at $2.94M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.